Skip to content

Home | About | History

HISTORY

2008


  • Breakthrough human immunogenicity data with Vaxfectin®-formulated pandemic influenza DNA vaccines
  • AnGes MG filed for Japanese approval of its Collategene™ angiogenesis product
  • Encouraging interim immunogenicity data from CMV vaccine Phase 2 HCT trial

2007


  • Merial received conditional USDA approval of canine melanoma vaccine
  • AnGes MG stopped Phase 3 angiogenesis trial early upon meeting statistical significance
  • Sanofi-aventis initiated Phase 3 angiogenesis trial
  • Initiated Phase 1 trial of pandemic influenza vaccine

2006


  • Initiated high-dose Allovectin-7® Phase 3 registration trial for metastatic melanoma
  • CMV vaccine Phase 2 trial opened for hematopoietic stem cell transplant donors and recipients
  • Demonstrated 100% protection in ferrets against H5N1 influenza with single vaccination
  • Completed three registered direct placements of stock with net proceeds totaling $47 million

2005


  • Aqua Health (Novartis) vaccine for salmon received approval in Canada
  • Established angiogenesis collaboration with AnGes MG
  • Merck initiated cancer vaccine Phase 1 trial
  • Completed Special Protocol Assessment of Phase 3 pivotal trial for Allovectin-7®
  • Completed registered direct placement of stock with net proceeds of $21 million

2004


  • Conducted Phase 1 testing of bivalent and trivalent CMV vaccine candidates
  • Completed registered direct placement of stock with net proceeds of $17+ million

2003


  • Moved to new facility to consolidate operations and upgrade manufacturing capacity

2002


  • Issuance of broad patent covering DNA delivery of proteins
  • Awarded first manufacturing contract for Vaccine Research Center of NIH
  • Merial exercised options for specific animal health vaccine indications

2001


  • High-dose Allovectin-7® entered Phase 2 registration trials for melanoma
  • Merck initiated human testing of a prime-boost HIV vaccine regimen
  • Appointed prestigious Scientific Advisory Board
  • Issuance of key DNA vaccine patent
  • Issuance of key University of Michigan patent, licensed to Vical
  • Gained access to DNA delivery enhancing technologies

2000


  • Completed f ollow-on offering of stock with net proceeds of $118 million
  • Entered strategic partnership with Human Genome Sciences

1999


  • Pfizer licensed gene delivery technology for animal health applications
  • Merck initiated DNA HIV vaccine trial
  • Merial selected initial targets for animal health DNA vaccines

1998


  • Patent issued for lipid-mediated DNA delivery
  • Low-dose Allovectin-7® entered Phase 3 registration trials for melanoma

1997


  • Additional patents issued for DNA delivery applications
  • Allovectin-7® started Phase 2 trial for head and neck cancer
  • Merck licensed DNA delivery technology for therapeutic vaccines against infectious diseases

1996


  • Merck started Phase 1 trial with DNA vaccine to prevent influenza
  • First patent issued from 1989 filing on core DNA delivery technology

1995


  • Allovectin-7® entered Phase 2 clinical trials for melanoma
  • Merial licensed DNA vaccines for veterinary applications
  • Follow-on offering in September of 2,500,000 shares at $12.25

1994


  • Allovectin-7® entered Phase 1 clinical trials for melanoma
  • Merck expanded infectious disease vaccine license
  • Aventis Pasteur licensed DNA delivery technology for infectious disease vaccines

1993


  • Initial public offering in March of 2,000,000 shares at $5.00
  • Follow-on offering in July of 2,000,000 shares at $7.00

1991


1989


1987


  • Incorporated in April to research & develop proprietary lipid chemistry
Back to Top